Company Overview and News


Add AMDA
to your dashboard

Headline News

Amedica's (AMDA) CEO Sonny Bal on Q3 2017 Results - Earnings Call Transcript

6h seekingalpha
Good day ladies and gentlemen and welcome to the Third Quarter 2017 Amedica Corporation Financial Results Conference Call. As a reminder this conference is being recorded. (34-0)

BRIEF-Amedica announces reverse stock split

2017-11-10 reuters
* Amedica Corp - ‍announced a 1-for-12 reverse stock split of its issued and outstanding common stock​ Source text for Eikon: Further company coverage: (19-0)

Amedica Announces Adjournment Of Special Meeting Of Stockholders

2017-10-03 devicespace
SALT LAKE CITY,, Oct. 03, 2017 (GLOBE NEWSWIRE) -- Amedica Corporation (Nasdaq:AMDA), an innovative medical device company that develops and commercializes silicon nitride, announced that the special meeting of stockholders scheduled for today has been adjourned. (34-1)

Orthopedic Biomaterials Market 13.19% CAGR by 2021 Biodegradable and Biocompatible Product Demand Rising

2017-09-29 prnewswire
Global Orthopaedic Biomaterial Market driven by rising clinical education among the patients, increasing medical applications of biomaterial by orthopaedicians, rising demand from the aged population, and technological innovation has further led to growing focus towards healthcare, hence, building the need for joint replacement surgeries using orthopaedic biomaterial, specifically among the adult population according to ReportsnReports. (37-2)

Amedica Announces Adjournment of Special Meeting of Stockholders

2017-09-27 marketwired
SALT LAKE CITY, UT--(Marketwired - Sep 27, 2017) - Amedica Corporation (NASDAQ: AMDA), an innovative medical device company that develops and commercializes silicon nitride, announced that the special meeting of stockholders scheduled for today has been adjourned. (34-1)

Amedica Releases First and Second Quarter 2017 Preliminary Unaudited Earnings Report and Business Update

2017-09-22 marketwired
SALT LAKE CITY, UT--(Marketwired - Sep 22, 2017) - Amedica Corporation (NASDAQ: AMDA), a company that develops and commercializes silicon nitride for biomedical applications, today announced its preliminary earnings report for the first and second quarters ended March 31, 2017 and June 30, 2017, respectively, and provided a business update related to its business strategy and certain recent developments. (34-0)

Amedica Releases First And Second Quarter 2017 Preliminary Unaudited Earnings Report And Business Update

2017-09-22 devicespace
SALT LAKE CITY, UT--(Marketwired - September 22, 2017) - Amedica Corporation (NASDAQ: AMDA), a company that develops and commercializes silicon nitride for biomedical applications, today announced its preliminary earnings report for the first and second quarters ended March 31, 2017 and June 30, 2017, respectively, and provided a business update related to its business strategy and certain recent developments. (34-0)

BRIEF-‍Amedica files for non-timely 10-Q ​

2017-08-16 reuters
* ‍Amedica Corp files for non-timely 10-q - sec filing ​ Source text - bit.ly/2i5VeDu Further company coverage:

Amedica Announces Adjournment of Special Meeting of Stockholders

2017-08-14 marketwired
SALT LAKE CITY, UT--(Marketwired - Aug 14, 2017) - Amedica Corporation (NASDAQ: AMDA), an innovative medical device company that develops and commercializes silicon nitride, announced that the special meeting of stockholders scheduled for today has been adjourned, with the adjournment itself being the only business conducted.

Is Amedica a Value Proposition at These Levels?

2017-06-22 accesswire
NEW YORK, NY / ACCESSWIRE / June 22, 2017 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report with no obligation on Amedica Corporation (NASDAQ: AMDA), a commercial-stage biomaterial company that develops, manufactures, and sells a range of medical devices based on its silicon nitride ceramic technology platform in the United States, Europe, and South America.

CORRECTION - Amedica Releases 2016 Preliminary Unaudited Earnings Report and Business Update

2017-06-09 marketwired
SALT LAKE CITY, UT--(Marketwired - Jun 9, 2017) - In the news release, "Amedica Releases 2016 Preliminary Earnings Report and Business Update," issued earlier today by Amedica Corporation (NASDAQ: AMDA), we are advised by the company that the this press release has been amended to reflect an increase in preliminary revenue, an increase in fourth quarter 2015 net loss per share, an adjustment to the decrease in cash and equivalents, and, to reflect that certain financial data in the Business Update and Related Developments section are unaudited.

Amedica Releases 2016 Preliminary Earnings Report and Business Update

2017-06-08 marketwired
SALT LAKE CITY, UT--(Marketwired - Jun 8, 2017) - Amedica Corporation (NASDAQ: AMDA), a company that develops and commercializes silicon nitride for biomedical applications, today announced its preliminary earnings report for the fourth quarter and fiscal year ended December 31, 2016 and provided a business update related to its business strategy and certain recent developments.

Amedica Announces Delayed Filing of Quarterly Report on Form 10-Q and Receipt of Nasdaq Letter

2017-05-26 marketwired
SALT LAKE CITY, UT--(Marketwired - May 26, 2017) - Amedica Corporation (NASDAQ: AMDA), an innovative biomaterial company which develops and manufactures silicon nitride as a platform for biomedical applications, announced today that it has delayed the filing of its Quarterly Report on Form 10-Q for the quarter ended March 31, 2017 ("Form 10-Q").

Stock Research Report

Amedica Corporation is a materials company focused on developing, manufacturing and selling silicon nitride ceramics that are used in medical implants and in a variety of industrial devices. At present, the company commercialize silicon nitride in the spine implant market. The company believe that its silicon nitride manufacturing expertise positions it favorably to introduce new and innovative devices in the medical and non- medical fields. The company also believe that Amedica is the first and only company to commercialize silicon nitride medical implants.

Amedica has received 510(k) regulatory clearance in the United States, a CE mark in Europe, and ANVISA approval in Brazil for a number of its devices that are designed for spinal fusion surgery. To date, more than 28,000 of its silicon nitride devices have been implanted into patients, with an 8-year successful track record. The company intend to file an FDA 510(k) submission for clearance in the United States of a novel compos...

Click for full article
CUSIP: 023435209